Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Survey

Voxeleron's Orion Ophthalmic Image Analysis Platform Reduces Variability of Clinical Trial Outputs


Voxeleron, a cloud-based ophthalmic image analysis platform provider, announced today the results of a study demonstrating its Orion platform delivers higher accuracies and reduced variability when compared to original equipment manufacturer (OEM) software from Carl Zeiss Cirrus and Heidelberg Spectralis. The study used Orion to analyze optical coherence tomography (OCT) images from the two manufacturers and clearly showed greater accuracy while reducing variability, and achieving both within a more streamlined workflow.

To fulfill recruitment goals, large clinical trials must use images from numerous sites utilizing different imaging vendor systems. For OCT images, the difference is not just in terms of the data formats, but also in terms of the analysis results. Most OEM software programs can introduce bias that can negatively affect study data. Orion is a vendor-neutral platform that both reads and processes OCT images from multiple devices within a common platform, significantly consolidating and minimizing a reading center's requirements for software and devices. In addition, Orion offers an intuitive interface to reduce errors while speeding up reading center workflow.

"We selected Orion to maximize efficiencies and minimize errors," said Jason S. Slakter, MD, Medical Director of World Care Clinical. "As this recent study demonstrates, Orion offers the most intuitive and accurate common-platform OCT analysis methods available, which provides advantages that we directly pass along to the trial sponsors."

"Our team created Orion to address critical technology gaps in OCT analysis platforms," said Jonathan Oakley, Co-founder of Voxeleron. "The most important gap being inter-operability, and we are delighted to share the results of the work as we continue to highlight its role in enabling successful ophthalmic clinical trials and, ultimately, better patient outcomes."

Voxeleron continues to expand its AI-enabled ophthalmic analysis offerings, and will be showcasing these at the upcoming ARVO 2023 Conference on April 23-27 in New Orleans, Louisiana.

About Voxeleron

Voxeleron is the innovative leader in AI-backed ophthalmic image analysis, delivering a powerful platform that interprets millions of measurements across multiple formats to translate clinical research data into valid, actionable results. By optimizing all aspects of clinical eye research, from initial trial recruitment through post-hoc analysis, Voxeleron is bringing comprehensive eye health into focus and helping eradicate diseases affecting tens of millions. Learn more at voxeleron.com.

About DARC/WorldCare Clinical

WorldCare Clinical is the leading independent CRO dedicated to imaging in clinical trials. Our approach is to combine imaging expertise, innovative technology, and operational excellence to maximize the precision and accuracy of a blinded independent central review of clinical trial data. We have performed imaging services on more than 1,000 clinical trials. From clinical operations and regulatory affairs specialists to data management experts, WCC offers an unprecedented wealth of resources to ensure an efficient and successful trial process and outcome. Learn more at wcclinical.com.


These press releases may also interest you

at 02:17
Fun88, a leading company in sports and entertainment, proudly announces its official title sponsorship with the Vizag Warriors for the Andhra Premier League (APL)....

at 02:10
KLab Inc., a leader in online mobile games, announced that its hit 3D action game Bleach: Brave Souls will be holding a Bleach: Brave Souls 9th Anniversary Bankai Live! on Sunday, July 14, 2024 from 18:30 (JST/UTC+9). See the original press release...

at 02:00
Azentio Software ("Azentio") - a leading end-to-end software company specializing in the BFSI sector, today announced the appointment of Aarthi Ramesh as Chief Customer Officer and Emma Foley as Chief Marketing Officer....

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

at 01:05
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Bel Group, today announced their long-term partnership to accelerate the food industry's transformation toward a more sustainable model. The companies will play a pivotal role in shaping...



News published on and distributed by: